SCM
FDMT icon

Silverarc Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Silverarc Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$750K – 77
2025
Q4 		$750K Buy
+100,000
New +$1.01M 0.1% 63

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's FDMT Position: Q1 2026 in Review

Silverarc Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 100,000 shares — an estimated $750K sold.

Silverarc Capital Management first reported a position in FDMT in Q4 2025 and held it in 1 quarter. The position peaked at $750K in Q4 2025. 153 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Silverarc Capital Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 100,000 4D Molecular Therapeutics shares in Q1 2026, an estimated $750K.
  • Silverarc Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2025 and held it in 1 quarter.
  • Silverarc Capital Management's 4D Molecular Therapeutics position peaked at $750K in Q4 2025.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.